foscarnet has been researched along with Hypocalcemia in 11 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Hypocalcemia: Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypocalcemia and an increase in creatinine level are the most important serious effects associated with foscarnet (PFA) therapy." | 7.69 | Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. ( Beauchamp, D; Bergeron, MG; Désormeaux, A; Dusserre, N; Omar, RF; Poulin, L; Tremblay, M, 1995) |
| "Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia." | 7.68 | Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991) |
| "Foscarnet (Foscavir) is an antiviral drug for intravenous (i." | 5.28 | Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs. ( Lundström, J; Nordgren, T; Ryrfeldt, A, 1992) |
| "Hypocalcemia and an increase in creatinine level are the most important serious effects associated with foscarnet (PFA) therapy." | 3.69 | Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. ( Beauchamp, D; Bergeron, MG; Désormeaux, A; Dusserre, N; Omar, RF; Poulin, L; Tremblay, M, 1995) |
| "An AIDS patient experienced an exacerbation of cytomegalovirus retinitis and was treated with foscarnet." | 3.68 | Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. ( Gearhart, MO; Sorg, TB, 1993) |
| "Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia." | 3.68 | Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991) |
| "Penile ulcers are best managed by stopping the infusion until the ulcers heal; they may be prevented by paying careful attention to personal hygiene." | 2.40 | Minimising the dosage-limiting toxicities of foscarnet induction therapy. ( Jayaweera, DT, 1997) |
| "Foscarnet (Foscavir) is an antiviral drug for intravenous (i." | 1.28 | Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs. ( Lundström, J; Nordgren, T; Ryrfeldt, A, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 8 (72.73) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ota, R | 1 |
| Hirata, A | 1 |
| Kindelan, JM | 1 |
| García-Lázaro, M | 1 |
| García-Herola, A | 1 |
| Jurado, R | 1 |
| Gearhart, MO | 1 |
| Sorg, TB | 1 |
| Chakrabarti, J | 1 |
| Omar, RF | 1 |
| Dusserre, N | 1 |
| Désormeaux, A | 1 |
| Poulin, L | 1 |
| Tremblay, M | 1 |
| Beauchamp, D | 1 |
| Bergeron, MG | 1 |
| Jayaweera, DT | 1 |
| Guillaume, MP | 1 |
| Karmali, R | 1 |
| Bergmann, P | 1 |
| Cogan, E | 1 |
| Huycke, MM | 1 |
| Naguib, MT | 1 |
| Stroemmel, MM | 1 |
| Blick, K | 1 |
| Monti, K | 1 |
| Martin-Munley, S | 1 |
| Kaufman, C | 1 |
| Ryrfeldt, A | 1 |
| Nordgren, T | 1 |
| Lundström, J | 1 |
| Jacobson, MA | 1 |
| Gambertoglio, JG | 1 |
| Aweeka, FT | 1 |
| Causey, DM | 1 |
| Portale, AA | 1 |
| Youle, MS | 1 |
| Clarbour, J | 1 |
| Gazzard, B | 1 |
| Chanas, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for foscarnet and Hypocalcemia
| Article | Year |
|---|---|
Minimising the dosage-limiting toxicities of foscarnet induction therapy.
Topics: Animals; Antiviral Agents; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Female; Fos | 1997 |
1 trial available for foscarnet and Hypocalcemia
| Article | Year |
|---|---|
A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Calcium; Cross-Ove | 2000 |
9 other studies available for foscarnet and Hypocalcemia
| Article | Year |
|---|---|
Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet.
Topics: Adult; Aged; Antiviral Agents; Creatinine; Cytomegalovirus Infections; Electrolytes; Female; Foscarn | 2021 |
[Hypocalcemia in a patient with the acquired immunodeficiency syndrome treated only with foscarnet].
Topics: Acquired Immunodeficiency Syndrome; Adult; Fatal Outcome; Foscarnet; HIV-1; Humans; Hypocalcemia; Ma | 1994 |
Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.
Topics: Adult; Cytomegalovirus Infections; Foscarnet; HIV Infections; Hospitals, Community; Hospitals, Teach | 1993 |
Endocrine effects of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Foscarnet; Humans; Hypocalcemia; Magnesium; Pentamidine | 1993 |
Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.
Topics: Animals; Antiviral Agents; Calcium; Dose-Response Relationship, Drug; Drug Carriers; Female; Foscarn | 1995 |
Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Humans; Hypocalcemia; Magnesium; Ma | 1997 |
Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs.
Topics: Animals; Blood Cell Count; Calcitriol; Dogs; Foscarnet; Homeostasis; Hypocalcemia; Infusions, Intrav | 1992 |
Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
Topics: Antiviral Agents; Calcium; Dose-Response Relationship, Drug; Foscarnet; Herpes Simplex; Humans; Hypo | 1991 |
Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine.
Topics: Acquired Immunodeficiency Syndrome; Amidines; Foscarnet; Humans; Hypocalcemia; Organophosphorus Comp | 1988 |